Colossal Risks Spectacle Over Conservation

The core risk is that Colossal can raise money on spectacle faster than it can build a durable business on conservation. Its clearest near term cash engines are much more practical than mammoths or dire wolves, pet and horse cloning through ViaGen, biobanking and genomics work with agencies, licensing tools built for editing and reproductive biology, and spinouts that package platform technology into simpler products with shorter sales cycles.

• ViaGen is the most concrete revenue line because it sells an immediate service. A customer stores tissue, ViaGen makes embryos from those cells, uses surrogates, and delivers a cloned pet or horse. That is a normal cash transaction, not a decade long science project.
  1 sacra
• Government work can fund conservation infrastructure before de extinction pays. The June 25, 2026 partnership with the U.S. Department of the Interior centers on biobanking and genomic science for threatened species, which fits BioVault and related services better than headline animal launches.
  3 doi
• The pressure comes from the financing bar. Colossal announced a $10.2B valuation in January 2025 after raising $200M, and reports in July 2026 said it was seeking a much higher valuation. At that scale, investors usually want visible progress and monetization long before ecological deployment is possible.
  5 colossal 6 axios 7 bizjournals

This points toward a company that increasingly looks like a synthetic biology holding company. The winning path is to turn de extinction R&D into cloning services, conservation infrastructure, government programs, and licensable tools that can finance the brand mission, instead of relying on each new animal reveal to carry the business forward.